The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Furiex Pharmaceuticals, Inc. (“Furiex” or the “Company”) (NasdaqGS: FURX) and other violations of state law by the board of directors of Furiex relating to the proposed buyout of the Company by Forest Laboratories, Inc. (“Forest”).

Under the terms of the transaction, Furiex shareholders will receive $95.00 per share in cash for each share of Furiex stock they own. An additional $30.00 per share may be payable to shareholders in a Contingent Value Right (CVR) based on the status of eluxodoline, Furiex’s lead product, as a controlled drug following approval. The firm’s investigation seeks to determine, among other things, whether the Company’s board of directors breached their fiduciary duties by failing to maximize shareholder value before agreeing to enter into this transaction, and whether Forest is underpaying for Furiex shares.

If you currently own common stock of Furiex and would like to learn more about the investigation being conducted by Brower Piven, without cost or obligation to you, click here:

You may also request more information by contacting Brower Piven either by email at or by telephone at (410) 415-6616. Attorneys at Brower Piven together have more than a century of experience litigating securities and other class action cases.

Copyright Business Wire 2010